Lannett Inc. (LCI)
NYSE: LCI
· Real-Time Price · USD
0.69
0.03 (4.55%)
At close: Apr 19, 2023, 9:58 PM
Lannett Revenue Breakdown
| Period Ending | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 | Jun 30, 2016 | Jun 30, 2015 | Jun 30, 2014 | Jun 30, 2013 | Jun 30, 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Analgesic Revenue | 15.74M | 14.68M | 8.68M | 101.47M | 64.01M | 50.63M | 53.54M | 55.17M | 62.12M | 25.88M | 18.14M |
| Analgesic Revenue Growth | +7.17% | +69.17% | -91.45% | +58.51% | +26.43% | -5.44% | -2.95% | -11.20% | +140.07% | +42.63% | n/a |
| Anti-Psychosis Revenue | 11.79M | 65.99M | 88.58M | 34.17M | 31.79M | 39.45M | 36.29M | n/a | n/a | n/a | n/a |
| Anti-Psychosis Revenue Growth | -82.13% | -25.50% | +159.22% | +7.49% | -19.42% | +8.71% | n/a | n/a | n/a | n/a | n/a |
| Cardiovascular Revenue | 45.38M | 95.11M | 77.26M | 48.57M | 60.29M | 71.89M | 52.7M | n/a | n/a | n/a | n/a |
| Cardiovascular Revenue Growth | -52.29% | +23.12% | +59.07% | -19.45% | -16.13% | +36.41% | n/a | n/a | n/a | n/a | n/a |
| Central Nervous System Revenue | 78.33M | 27.07M | 73.48M | 6.78M | 8.66M | 14.7M | 17.4M | n/a | n/a | n/a | n/a |
| Central Nervous System Revenue Growth | +189.34% | -63.16% | +983.25% | -21.68% | -41.06% | -15.54% | n/a | n/a | n/a | n/a | n/a |
| Contract manufacturing revenue Revenue | 11.67M | 67.54M | 73.24M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Contract manufacturing revenue Revenue Growth | -82.72% | -7.78% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Endocrinology Revenue | 27.49M | 67.76M | 4.22M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Endocrinology Revenue Growth | -59.43% | +1503.81% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gastrointestinal Revenue | 51.03M | 5.79M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gastrointestinal Revenue Growth | +781.89% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Infectious Disease Revenue | 28.01M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Infectious Disease Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Migraine Revenue | 16.32M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Migraine Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Revenue | 41.28M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Respiratory/Allergy/Cough/Cold Revenue | 8.96M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Respiratory/Allergy/Cough/Cold Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Urinary Revenue | 4.59M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Urinary Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 20.45M | 18.32M | 16.7M | 25.75M | 17.57M | 18.79M | 18.91M | 21.58M | 17.64M | 13.73M | 15.14M | 18.59M | 22.15M | 17.42M | 21.31M | 22.21M | 21.65M | 23.2M | 20.59M | 20.55M | 14.11M | 28.49M | 19.04M | 16.52M | 17.63M | 18.07M | 21.26M | 21.97M | 16.16M | 14.67M | 15.54M | 13.95M | 12.2M |
| Selling, General, and Administrative Revenue Growth | +11.62% | +9.70% | -35.17% | +46.57% | -6.49% | -0.60% | -12.38% | +22.34% | +28.45% | -9.29% | -18.58% | -16.06% | +27.13% | -18.24% | -4.08% | +2.61% | -6.67% | +12.67% | +0.17% | +45.64% | -50.47% | +49.66% | +15.25% | -6.30% | -2.44% | -15.01% | -3.21% | +35.95% | +10.17% | -5.60% | +11.39% | +14.29% | n/a |
| Research and Development Revenue | 7.11M | 4.93M | 7.18M | 6.04M | 5.81M | 4.75M | 5.76M | 6.02M | 5.97M | 5.64M | 6.54M | 6.69M | 7.44M | 6.91M | 8.94M | 9.44M | 9.84M | 9.72M | 9.81M | 8.34M | 2.73M | 10.72M | 7.41M | 11.42M | 8.34M | 9.94M | 12.37M | 12.96M | 16.5M | 9.07M | 6.53M | 6.98M | 9.16M |
| Research and Development Revenue Growth | +44.18% | -31.36% | +18.78% | +4.08% | +22.33% | -17.64% | -4.20% | +0.74% | +5.83% | -13.69% | -2.27% | -10.08% | +7.75% | -22.75% | -5.26% | -4.09% | +1.18% | -0.89% | +17.70% | +205.31% | -74.54% | +44.72% | -35.14% | +36.97% | -16.09% | -19.66% | -4.56% | -21.42% | +81.88% | +38.92% | -6.53% | -23.75% | n/a |